A. Sinclair Dunlop, Director at Apellis Pharmaceuticals, Inc. (APLS), sold 49,786 shares at $53.86 ($2.7M) on 2020-12-14, disclosed to the SEC on 2020-12-15.
Open-market sale of $2.7M APLS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.86 | 7,654 | $412K | 15.1% |
| 2 | $53.86 | 7,654 | $412K | 15.1% |
| 3 | $55.01 | 17,132 | $942K | 34.6% |
| 4 | $55.01 | 17,132 | $942K | 34.6% |
| 5 | $56.25 | 214 | $12K | 0.4% |
| Total | $54.66 avg | 49,786 |
| $2.7M |
| 100% |
| Filing → |
| APLS | SELL | 2025-09-19 | $1.4M | — | Filing → |
| APLS | SELL | 2024-09-17 | $2.7M | — | Filing → |
| APLS | SELL | 2024-06-21 | $2.9M | — | Filing → |